Drug Profile

OSCA

Alternative Names: FURESTEM-OA Kit Inj - Kangstem Biotech; Oscar - KangStem Biotech; Osiramestrocel CAM

Latest Information Update: 16 Oct 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Kangstem Biotech
Developer Kangstem Biotech; Yooyoung Pharmaceutical
Class Mesenchymal stem cell therapies
Mechanism of Action Cell replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase I/II Osteoarthritis

Most Recent Events

04 Sep 2025 Kangstem Biotech plans a pre-IND meeting with US FDA for Osteoarthritis in 2026
04 Sep 2025 Yuyoung Pharmaceutical and KangStem Biotech plans a phase-IIb trial for Osteoarthritis in South Korea (Intra-articular), (NCT06013306)
30 Apr 2025 Final adverse events and efficacy data from a phase-I trial in Osteoarthritis released by Kangstem Biotech

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com